文献速递炎症性肠病胃肠动力与功能性疾病

粪便微生物移植治疗复发性艰难梭菌感染的长期安全性

Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
PubMed 文献 · Gastroenterology · 2021-01-11

前瞻性调查研究纳入609例因复发性艰难梭菌感染接受粪便微生物移植(FMT)的患者,中位年龄56岁,64.8%为女性,22.8%有炎症性肠病。短期随访超过60%有腹泻,1年时9.5%报告额外CDI发作;长期随访447例中位3.7年,报告73例新诊断,感染均认为与FMT无关。结论认为FMT安全性较好,感染传播风险低。

要点

  • FMT治疗复发性CDI后感染传播风险低,长期安全性较好。
  • 炎症性肠病、透析依赖肾病和多次FMT与腹泻风险升高相关。
  • 长期随访中新诊断需未来研究进一步探索。

核心结论

  • FMT appears safe with low risk of transmission of infections.

研究设计与样本

  • Prospective survey-based study conducted September 2012-June 2018 in patients undergoing FMT for recurrent CDI.
  • Overall 609 patients underwent FMT; median age 56 years (range, 18-94), 64.8% women, 22.8% had inflammatory bowel disease.

主要发现

  • At short-term follow-up (n = 609), >60% of patients had diarrhea and 19%-33% had constipation.
  • At 1 year, 9.5% reported additional CDI episodes.
  • On multivariable analysis, patients with IBD, dialysis-dependent kidney disease, and multiple FMTs had higher risk of diarrhea; risk of constipation was higher in women and lower in IBD (all P < .05).
  • For long-term follow-up (n = 447), median time of follow-up was 3.7 years (range, 2.0-6.8); overall 73 new diagnoses were reported: 13% gastrointestinal, 10% weight gain, 11.8% new infections (all deemed unrelated to FMT).
  • Median time to infections was 29 months (range, 0-73) post-FMT.

临床怎么用

  • FMT治疗复发性CDI后感染传播风险低,支持其长期安全性。
  • 对合并IBD、透析依赖肾病或多次FMT的患者,应关注腹泻风险。
  • 长期随访中新诊断需进一步研究以明确与FMT的关系。

局限性

  • Survey-based study with potential nonresponse bias, weighted to account for it.
  • New diagnoses should be explored in future studies.

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fecal microbiota transplantation (FMT) is highly effective for treating recurrent Clostridioides difficile infection (CDI), with emerging data on intermediate and long-term safety. METHODS: A prospective survey-based study was conducted (September 2012-June 2018) in patients undergoing FMT for recurrent CDI. Data on demographics and comorbidities were abstracted from medical records. Patients were contacted at 1 week, 1 month, 6 months, 1 year (short-term), and ≥2 years post-FMT (long-term). Symptoms and new medical diagnoses were recorded at each time point. Data were weighted to account for survey nonresponse bias. Multivariate logistic regression models for adverse events were built using age (per 10-year increment), sex, time of survey, and comorbidities. P < .05 was considered statistically significant. RESULTS: Overall, 609 patients underwent FMT; median age was 56 years (range, 18-94), 64.8% were women, 22.8% had inflammatory bowel disease (IBD). At short-term follow-up (n = 609), >60% of patients had diarrhea and 19%-33% had constipation. At 1 year, 9.5% reported additional CDI episodes. On multivariable analysis, patients with IBD, dialysis-dependent kidney disease, and multiple FMTs had higher risk of diarrhea; risk of constipation was higher in women and lower in IBD (all P < .05). For long-term follow-up (n = 447), median time of follow-up was 3.7 years (range, 2.0-6.8). Overall, 73 new diagnoses were reported: 13% gastrointestinal, 10% weight gain, 11.8% new infections (all deemed unrelated to FMT). Median time to infections was 29 months (range, 0-73) post-FMT. CONCLUSION: FMT appears safe with low risk of transmission of infections. Several new diagnoses were reported, which should be explored in future studies.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Saha S, Mara K, Pardi DS, et al. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology. 2021. PMID: 33444573. doi:10.1053/j.gastro.2021.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。